Year: 2020

BERGENBIO HOSTING VIRTUAL R&D Day TODAY
Bergen, Norway, 06 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO PRESENTS PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT annual SITC meeting
Bergen, Norway, 11 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO TO PRESENT AT Sachs Annual Biotech in Europe Forum
Bergen, Norway, 18 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Bergen, Norway, 01 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020
Bergen, Norway, 18 August 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation
Bergen, Norway, 10 August 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More